What is InfoBionic.Ai?
InfoBionic.Ai is a Massachusetts-based healthcare technology firm dedicated to optimizing the economics and clinical efficiency of remote patient monitoring. By leveraging a seasoned team with deep expertise in cardiology, medical devices, and mobile IT, the company has developed the MoMe Kardia platform. This solution is engineered to eliminate the diagnostic bottlenecks inherent in legacy cardiac arrhythmia detection systems, thereby facilitating faster, data-driven clinical decision-making for physicians and improved outcomes for patients. The company occupies a critical niche at the intersection of digital health and specialized diagnostic hardware, positioning itself as a transformative force in the evolving landscape of value-based care.
How much funding has InfoBionic.Ai raised?
InfoBionic.Ai has raised a total of $70.7M across 7 funding rounds:
Other Financing Round
$1M
Private Equity
$969K
Other Financing Round
$1.2M
Series B
$8.2M
Unspecified
$50M
Debt
$350K
Debt
$9M
Other Financing Round (2012): $1M with participation from Broadview Ventures
Private Equity (2012): $969K led by Undisclosed
Other Financing Round (2013): $1.2M supported by Cherrystone Angel Group
Series B (2015): $8.2M featuring Excel Venture Management, Zaffre Investments, and Safeguard Scientifics
Unspecified (2018): $50M backed by Blue Cross and Blue Shield of Kansas, Eagle Investments, Excel Venture Management, Zaffre Investments, and Safeguard Scientifics
Debt (2020): $350K with participation from PPP
Debt (2021): $9M led by Horizon Technology Finance
Key Investors in InfoBionic.Ai
Zaffre Investments
A subsidiary of Blue Cross Blue Shield of Massachusetts, this firm focuses on healthcare innovation, providing strategic support and capital to companies improving healthcare delivery.
Safeguard Scientifics
A long-standing venture capital and private equity firm that provides growth capital and operational expertise to technology-driven businesses in the healthcare and financial services sectors.
Excel Venture Management
A venture capital firm specializing in life sciences and healthcare, focusing on companies that bridge the gap between technology and clinical application.
What's next for InfoBionic.Ai?
With a robust history of capital acquisition, InfoBionic.Ai is well-positioned to scale its operations and deepen its market penetration. The company's strategic trajectory suggests a focus on expanding the clinical utility of its remote monitoring suite, likely targeting broader adoption within health systems and accountable care organizations. As the firm transitions from its earlier development phases into a mature enterprise, the focus will shift toward operational excellence, regulatory scaling, and the continued refinement of its diagnostic algorithms. The ongoing support from institutional investors and strategic healthcare partners provides the necessary runway to sustain innovation in a highly competitive digital health market, ensuring that InfoBionic.Ai remains at the forefront of cardiac monitoring technology.
See full InfoBionic.Ai company page
